Document:

EXHIBIT 10.1

 

SIXTH AMENDMENT TO SECOND AMENDED

AND RESTATED CREDIT AGREEMENT

 

This SIXTH AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT
(this “Sixth Amendment”) is entered into as of March 9, 2016 and made by and among HARVARD BIOSCIENCE, INC. (the “Borrower”),
BANK OF AMERICA N.A., as Administrative Agent (“Agent”) L/C Issuer and Lender, and BROWN BROTHERS HARRIMAN & CO.
(“BBH”).

 

Background

 

The Borrower, the Agent and BBH entered into a Second Amended and
Restated Credit Agreement dated as of March 29, 2013, as amended by First Amendment to Second Amended and Restated Credit Agreement
dated May 30, 2013 with an effective date as of April 30, 2013, as amended by Second Amendment to Second Amended and Restated Credit
Agreement and Waiver dated October 31, 2013, as amended by Third Amendment to Second Amended and Restated Credit Agreement dated
April 24, 2015, as amended by Fourth Amendment to Second Amended and Restated Credit Agreement dated June 30, 2015, as amended
by Fifth Amendment to Amended and Restated Credit Agreement dated as of November 5, 2015 (collectively, the “Original Credit
Agreement”). Capitalized terms used herein but not defined herein will have the meaning given such term in the Original Credit
Agreement. The Borrower has requested that the Agent and the Lenders (i) amend the amortization of the Term Loan and the Amortizing
Revolver Borrowings and (ii) amend the Minimum Fixed Charge Coverage Ratio. The Original Credit Agreement, as amended by this Sixth
Amendment, as further amended, modified or supplemented from time to time, is referred to herein as the “Credit Agreement”.

 

NOW, THEREFORE, in consideration of the promises and the agreements,
provisions and covenants herein contained, the Borrower, the Agent and the Lenders hereby agree as follows:

 

1.                 
Amendment. Subject to the terms and conditions herein contained and in reliance on the representations and warranties
of the Borrower herein contained, effective upon satisfaction of the conditions precedent contained in section 2 below, the
following amendments shall be incorporated into the Original Credit Agreement:

 

(A)Section 2.07, “Repayment of Loans”
of the Original Loan Agreement is hereby deleted in its entirety and the following is hereby inserted in lieu thereof:

 

“2.07Repayment of Loans.

 

(a)Term Loans. The Borrower shall repay to the
Term Lenders, Three Hundred Thirty Seven Thousand Five Hundred Dollars ($337,500) on the last Business Day of each calendar quarter
commencing with a payment on March 30, 2016 and on the last Business Day of each calendar quarter thereafter (which amounts shall
be reduced as a result of the application of prepayments in accordance with Section 2.05 (b) (v)); provided, however,
that the final principal payment of the Term Loans shall be made on the Maturity Date for the Term Facility and in any event
shall be in an amount equal to the aggregate principal amount of all Term Loans outstanding on such date. No Term Loans may be
reborrowed.

 

    	 

     

    

(b)Amortizing Revolver Borrowings. No Additional
HART Revolver Borrowings will be made. The Borrower shall repay to the Revolving Credit Lenders, Two Hundred Seventy Five
Thousand Dollars ($275,000) on the last Business Day of each calendar quarter commencing on March 30, 2016 and on the last Business
Day of each calendar quarter thereafter(which amounts shall be reduced as a result of the application of prepayments in accordance
with Section 2.05 (b) (v)); provided, however, that the final principal payment of the Amortizing Revolver Borrowings
shall be made on the Maturity Date for the Amortizing Revolver Borrowings and in any event shall be in an amount equal to the aggregate
principal amount of all Amortizing Revolver Borrowings outstanding on such date. No Amortizing Revolver Borrowings may be reborrowed.

 

(c)Revolving Credit Loans. The Borrower shall repay to
the Revolving Credit Lenders on the Maturity Date for the Revolving Credit Facility the aggregate principal amount of all Revolving
Credit Loans outstanding on such date.

 

“(B)Section 7.11(b), “Financial
Covenants; Minimum Fixed Charge Coverage Ratio” of the Original Credit Agreement is hereby amended
by deleting the text therein contained in its entirety and replacing it with the following in lieu thereof:

 

“Minimum Fixed Charge Coverage Ratio.
As of the last day of any fiscal quarter, commencing with the fiscal quarter ending on March 30, 2016, and the last day of each
fiscal quarter thereafter, the ratio of (i) consolidated Adjusted EBITDA of the Borrower and its Subsidiaries (for the avoidance
of doubt, excluding HART) for the four-quarter period ending on the last day of such fiscal quarter, minus, (x) aggregate
cash capital expenditures, minus (y) cash taxes paid, each of (x) and (y) for the four-quarter period ending on the
last day such fiscal quarter, to (ii) the current portion of Funded Debt other than the Total Revolving Credit Outstandings, as
of the last day of such fiscal quarter, plus (without duplication) Interest Expense during such trailing four (4) fiscal
quarters, to be less than 1.25:1.00.”

 

2.                 
Conditions Precedent. The provisions of this Sixth Amendment shall be effective as of the date on which all of the
following conditions shall be satisfied:

 

(a)               
the Borrower shall have delivered to the Agent a fully executed counterpart of this Sixth Amendment;

 

(b)              
the Borrower shall have paid all fees, costs and expenses owing to the Agent and its counsel on or before the date hereof;
and

 

(c)               
the Lenders shall have indicated their consent and agreement by executing this Sixth Amendment.

 

    	 	2	 

     

    

3.                 
Miscellaneous.

 

(a)               
Ratification. The terms and provisions set forth in this Sixth Amendment shall modify and supersede all inconsistent
terms and provisions set forth in the Original Credit Agreement and except as expressly modified and superseded by this Sixth Amendment,
the terms and provisions of the Original Credit Agreement and the other Loan Documents are ratified and confirmed and shall continue
in full force and effect. The Borrower and the Agent agree that the Original Credit Agreement as amended hereby and the other Loan
Documents shall continue to be legal, valid, binding and enforceable in accordance with their respective terms. For all matters
arising prior to the effective date of this Sixth Amendment, the Original Credit Agreement (as unmodified by this Amendment) shall
control. The Borrower hereby acknowledges that, as of the date hereof, the security interests and liens granted to the Agent and
the Lender under the Credit Agreement and the other Loan Documents are in full force and effect, are properly perfected and are
enforceable in accordance with the terms of the Credit Agreement and the other Loan Documents.

 

(b)              
Representations and Warranties. The Borrower hereby represents and warrants to the Agent and the Lenders that
the representations and warranties set forth in the Loan Documents, after giving effect to this Sixth Amendment, are true and correct
in all material respects on and as of the date hereof, with the same effect as though made on and as of such date except with respect
to any representations and warranties limited by their terms to a specific date. The Borrower further represents and warrants to
the Agent and the Lenders that the execution, delivery and performance by the Borrower of this consent letter (i) are within
the Borrower’s power and authority; (ii) have been duly authorized by all necessary corporate and shareholder action; (iii)
are not in contravention of any provision of the Borrower’s certificate or articles of incorporation or bylaws or other organizational
documents; (iv) do not violate any law or regulation, or any order or decree of any Governmental Authority; (v) do not conflict
with or result in the breach or termination of, constitute a default under or accelerate any performance required by, any indenture,
mortgage, deed of trust, lease, agreement or other instrument to which the Borrower is a party or by which the Borrower or any
of its property is bound; (vi) do not result in the creation or imposition of any Lien upon any of the property of the Borrower
other than in favor of Agent; (vii) do not require the consent or approval of any Governmental Authority. All representations and
warranties made in this Sixth Amendment shall survive the execution and delivery of this Sixth Amendment, and no investigation
by the Agent shall affect the representations and warranties or the right of the Agent to rely upon them.

 

(c)               
Reference to Agreement. Each of the Loan Documents, including the Original Credit Agreement and any and all
other agreements, documents, or instruments now or hereafter executed and delivered pursuant to the terms hereof or pursuant to
the terms of the Original Credit Agreement as amended hereby, are hereby amended so that any reference in such Loan Documents to
the Original Credit Agreement shall mean a reference to the Original Credit Agreement as amended hereby.

 

(d)              
Expenses of the Agent. As provided in the Credit Agreement, the Borrower agrees to pay all reasonable costs
and expenses incurred by the Agent in connection with the preparation, negotiation, and execution of this Sixth Amendment, including
without limitation, the reasonable costs and fees of the Agent’s legal counsel.

 

    	 	3	 

     

    

(e)               
Severability. Any provision of this Sixth Amendment held by a court of competent jurisdiction to be invalid
or unenforceable shall not impair or invalidate the remainder of this Sixth Amendment and the effect thereof shall be confined
to the provision so held to be invalid or unenforceable.

 

(f)               
Applicable Law. This Amendment shall be governed by and construed in accordance with the laws of The Commonwealth
of Massachusetts and the applicable laws of the United States of America.

 

(g)              
Successors and Assigns. This Sixth Amendment is binding upon and shall inure to the benefit of the Agent,
the Lender and the Borrower, and their respective successors and assigns, except the Borrower may not assign or transfer any of
its rights or obligations hereunder without the prior written consent of the Agent.

 

(h)              
Counterparts. This Sixth Amendment may be executed in one or more counterparts and on facsimile counterparts,
each of which when so executed shall be deemed to be an original, but all of which when taken together shall constitute one and
the same agreement.

 

(i)                
Effect of Waiver. No consent or waiver, express or implied, by the Agent to or for any breach of or deviation
from any covenant, condition or duty by the Borrower shall be deemed a consent or waiver to or of any other breach of the same
or any other covenant, condition or duty.

 

(j)                
Headings. The headings, captions, and arrangements used in this Sixth Amendment are for convenience only and
shall not affect the interpretation of this Sixth Amendment.

 

(k)              
ENTIRE AGREEMENT. THIS SIXTH AMENDMENT EMBODIES THE ENTIRE AGREEMENT AMONG THE PARTIES HERETO WITH RESPECT
TO THE SUBJECT MATTER THEREOF, AND SUPERSEDES ANY AND ALL PRIOR REPRESENTATIONS AND UNDERSTANDINGS, WHETHER WRITTEN OR ORAL, RELATING
TO THIS AMENDMENT. THERE ARE NO ORAL AGREEMENTS AMONG THE PARTIES HERETO WITH RESPECT TO THE SUBJECT MATTER HEREOF.

 

[Remainder of Page Intentionally Left Blank]

 

    	 	4	 

     

    

IN WITNESS WHEREOF, the parties hereto have executed this Sixth Amendment
as of the date first above written.

 

BORROWER

 

HARVARD BIOSCIENCE, INC.

 

By:/s/ Robert E. Gagnon

Name: Robert E. Gagnon

Title: CFO

 

AGENT

 

BANK OF AMERICA, N.A., as Agent

 

By: /s/ Renee Marion

Name: Renee Marion

Title: Assistant Vice President

 

LENDERS

 

BANK OF AMERICA, N.A., as a Lender

 

By: /s/ Peter McCarthy

Name: Peter McCarthy

Title: SVP

 

BROWN BROTHERS HARRIMAN & CO., as a Lender

 

By: /s/ Daniel G. Head 

Name: Daniel G. Head

Title: Senior Vice PresidentExhibit 10.1

 

ARGOS THERAPEUTICS, INC.

4233 TECHNOLOGY DRIVE

DURHAM, NC 27704

 

 

December 2, 2015

 

VIA email

 

Lee F. Allen

3 Paniolo Road

Ladera Ranch, CA 92656

 

Dear Lee:

 

I am pleased to extend to you this offer of employment with Argos
Therapeutics, Inc. (“Argos Therapeutics”) by way of this offer letter (the “Offer Letter”).
We at Argos Therapeutics are excited about the challenges and opportunities that lie ahead for us collectively and are enthusiastic
about the prospect of you joining the Argos Therapeutics team. We look forward to your favorable response to this. If you choose
to accept the Company’s offer, your employment at Argos Therapeutics shall commence no later than January 18, 2016.

 

The details of this offer are as follows:

 

		1.	Position and Duties.  You shall serve, on a full-time basis, as the Company’s
Chief Medical Officer reporting to the Company’s Chief Executive Officer.  You agree to continue to perform the duties
of your position and such other duties as reasonably may be assigned to you from time to time.  You also agree that while
employed by the Company, you will continue to devote your full business time and your best efforts, business judgment, skill and
knowledge exclusively to the advancement of the business and interests of the Company and to the discharge of your duties and responsibilities
for it, except as approved by the Company.

 

		2.	Compensation and Benefits.  During your employment, as compensation for all services
performed by you for the Company and subject to your performance of your duties and responsibilities for the Company, pursuant
to this Agreement or otherwise, the Company will provide you the following pay and benefits:

 

		(a)	Base Salary. Your base salary in this position will be at the rate of $425,000 per year,
less all applicable taxes and deductions, and shall be paid semi-monthly in accordance with the Company’s standard payroll
schedule. First and last payments will be adjusted to reflect partial periods worked.

 

		(b)	Bonus Compensation. During your employment and subject to the approval of the Company’s
Board of Directors (the “Board”), you will be eligible for an annual performance bonus of up to 40% of your
annualized base salary (the “Target Bonus”), based upon your personal performance and the Company’s performance
during the applicable calendar year, as determined by the Company in its sole discretion. Any bonus due to you hereunder will be
paid not later than the 15th of March following the year to which the bonus relates, subject to your continuous employment
through the date the bonus is paid.  The foregoing shall be construed and applied so that any bonus payable to you is paid
to you so as to qualify as a “short-term deferral” under Section 409A of the Internal Revenue Code of 1986, as
amended (the “Code”) (Section 409A of the Code, together with the regulations thereunder, “Section 409A”).

 

		(c)	Starting Bonus. You will be eligible for a starting bonus in the aggregate amount of $230,000, less all applicable taxes
and deductions. This bonus shall be paid in three installments, with the first installment of $75,000 payable with your first semi-monthly
salary payment. The second installment of $75,000 will be payable with your first salary payment after completing three months
of service with the Company. The final installment of $80,000 will be payable with your first salary payment after completing six
months of service with the Company. If you voluntarily terminate your employment with the Company prior to the one-year anniversary
of your start date, you will be required to reimburse the Company for the full amount of the starting bonus paid to you.

 

    	A-1

     

    

 

		(d)	Equity. Subject to the approval of the Board of Directors or the Compensation Committee
and in accordance with the terms and conditions of the Company’s 2014 Stock Incentive Plan and the terms of the Company’s
standard Incentive Stock Option Agreement, you will be granted stock options to purchase 300,000 of Argos Therapeutics common stock
at an exercise price equal to the closing share price on the date of grant, which will generally be within ninety days of the start
of your employment. The options will vest over four years from your start date while you are employed in accordance with the applicable
plan and stock option agreement. 300,000 shares is equal to approximately 1.45% of Argos’ total shares outstanding as of
the date of this letter agreement. As you know, Argos anticipates undertaking an equity financing during early 2016 which will
have the effect of reducing the percentage interest in Argos represented by these stock options. To mitigate the dilutive effect
of the planned financing on your interest in Argos, Argos agrees to grant you additional stock options within sixty days following
Argos’ next equity financing such that you will hold stock options for a number of shares equal to no less than 1.25% of
Argos’ total shares outstanding at the time the grant is made. These supplemental stock options will have an exercise price
equal to the closing share price on the date of grant, will vest over four years from your start date and will be subject to the
Company’s 2014 Stock Incentive Plan and the terms of the Company’s standard Incentive Stock Option Agreement.

 

		(e)	Participation in Employee Benefit Plans.  You will be entitled to participate in all
employee benefit plans from time to time in effect for employees of the Company generally, except to the extent such plans are
duplicative of benefits otherwise provided to you under this Agreement (e.g., severance pay) or under any other agreement. 
Your participation will be subject to eligibility and the terms of the applicable plan documents and applicable Company policies.
Argos Therapeutics provides the following benefits to regular, full-time employees includes the following:

			

		·	Medical Insurance

		·	Dental Insurance

		·	Vision Insurance

		·	Life and AD&D Insurance

		·	Short Term Disability

		·	Long Term Disability

		·	Long Term Care

		·	Eleven paid holidays per year

		·	401(k) Savings and Investment Plan

		·	Flexible Spending Account

		·	Paid Time Off (PTO) eligibility based on service with the Company and initially prorated at 16.67
hours per month (equivalent to 25 days per year)

Notes:

		o	Argos Therapeutics pays 100% of all individual benefit premiums and 50% of dependent premiums.

		o	If your employment terminates for any reason whatsoever, you may not be entitled to receive any
cash payment for unused paid time off accrued to the date of your termination.

 

Argos Therapeutics will regularly review all its benefit
plans and reserves the right to change or terminate such plans at any time at its sole discretion, with or without prior notice
to you.

 

    	A-2

     

    

 

		(f)	Relocation Expenses. To help ease the burdens resulting from your relocation from California
to the Raleigh-Durham area of North Carolina, Argos Therapeutics has agreed to provide you with certain temporary living and relocation
expenses provided that you sign and return the enclosed Relocation Expense Letter Agreement prior to commencing your employment
at the Company. All moving related expenses must be documented and requests for reimbursement be made in accordance with the Company’s
standard reimbursement policy. By signing this Offer Letter and the enclosed Relocation Expense Letter Agreement, you acknowledge
and agree that if you voluntarily terminate your employment with the Company, without Good Reason (defined below), prior to the
one-year anniversary of your start date, you will be required to reimburse the Company for the full amount of any moving and temporary
living expenses for which the Company has reimbursed you.

 

		(g)	Business Expenses.  The Company will pay or reimburse you for all reasonable business
expenses incurred or paid by you in the performance of your duties and responsibilities for the Company, subject to any maximum
annual limit and other restrictions on such expenses set by the Company and to such reasonable substantiation and documentation
as the Company may specify from time to time.  Any reimbursement that constitutes nonqualified deferred compensation subject
to Section 409A shall be subject to the following additional rules: (i) no reimbursement of any such expense shall affect
your right to reimbursement of any other such expense in any other taxable year; (ii) reimbursement of the expense shall be
made, if at all, not later than the end of the calendar year following the calendar year in which the expense was incurred; and
(iii) the right to reimbursement shall not be subject to liquidation or exchange for any other benefit.

 

		3.	Severance. The Company will provide you with the following severance payments as a condition
of your employment:

 

		(a)	Termination Without Cause or for Good Reason. If your employment is terminated by
the Company Without Cause or by you for Good Reason, then (subject to your executing and not revoking the Separation Agreement
and Release of All Claims (the “Release,” attached hereto as Exhibit A), the Company will: (i)
pay you an amount equal to 9 months of your then-current base salary, less standard employment-related withholdings and deductions,
with such payments to be made in 9 equal monthly installments in accordance with the Company’s usual payroll practices beginning
on the first regular pay date following the termination date; and (ii) provide for continued coverage, at the Company’s expense,
under the Company’s medical plan to the extent permitted under such plans for a period of 9 months immediately following
the date of termination of your employment; provided, however, that if health insurance coverage is not available to non-employees
under the Company sponsored plan, the Company shall reimburse you in an amount equal to the cost of the premium for coverage under
a medical plan at the same average level and on the same terms and conditions which applied immediately prior to the date of your
termination.

 

		(b)	Termination Without Cause or for Good Reason Following a Change in Control. Notwithstanding
the foregoing, if your employment is terminated by the Company or its successor in interest Without Cause or by you for Good Reason
within ninety (90) days before or within six months after a Change in Control Event (as defined in the Company’s 2014 Stock
Incentive Plan) that also qualifies as a “change in control event” within the meaning of Treasury Regulation Section
1.409A-3(i)(5)(i) (a “Company Change in Control”) then (subject to your executing and not revoking the Release)
the Company will (i) pay you an amount equal to 15 months of your then-current base salary, less standard employment-related
withholdings and deductions, with such payments to be made in 15 equal monthly installments in accordance with the Company’s
usual payroll practices beginning on the first regular pay date following the termination date; (ii) pay you an amount equal to
15 months of the Target Bonus, less standard employment-related withholdings and deductions, with such payments to be made in 15
equal monthly installments in accordance with the Company’s usual payroll practices beginning on the first regular pay date
following the termination date; and (iii) provide for continued coverage, at the Company’s expense, under the Company’s
medical plan to the extent permitted under such plans for a period of 15 months immediately following the date of termination of
your employment; provided, however, that if health insurance coverage is not available to non-employees under the Company sponsored
plan, the Company shall reimburse you in an amount equal to the cost of the premium for coverage under a medical plan at the same
average level and on the same terms and conditions which applied immediately prior to the date of your termination.

 

    	A-3

     

    

 

		(c)	Definition of “Cause.” For purposes hereof, “Cause” shall
mean that: (i) you failed to attempt in good faith, refused or willfully neglected to perform and discharge your material
duties and responsibilities; (ii) you have been convicted of, or pled nolo contendere to, a felony or other crime
involving fraud or moral turpitude; (iii) you breached your fiduciary duty or loyalty to the Company, or acted fraudulently
or with material dishonesty in discharging your duties to the Company; (iv) you undertook an intentional act or omission of
misconduct that materially harmed or was reasonably likely to materially harm the business, interests, or reputation of the Company;
(v) you materially breached any material provision hereof; or (vi) you materially breached any material provision of
any Company code of conduct or ethics policy. Notwithstanding the foregoing, “Cause” shall not be deemed to have occurred
unless: (A) the Company provides you with written notice that it intends to terminate your employment hereunder for one of
the grounds set forth in subsections (i), (v) or (vi) within sixty (60) days of such reason(s) occurring, (B) if
such ground is capable of being cured, you have failed to cure such ground within a period of thirty (30) days from the date
of such written notice, and (C) the Company terminates your employment within six (6) months from the date that Cause
first occurs.

 

		(d)	Definition of “Good Reason.” For purposes hereof, “Good Reason”
shall mean, without your written consent: (i) any change in your position, title or reporting relationship with the Company
that diminishes in any material respect your authority, duties or responsibilities; provided, however,
that a change in your authority, duties or responsibilities solely due to the Company becoming a division, subsidiary or other
similar part of a larger organization, shall not by itself constitute Good Reason; (ii) any material reduction in your base
compensation; (iii) a material change in the geographic location at which services are to be performed by you; or (iv) a
material breach of any provision hereof by the Company or any successor or assign. Notwithstanding the foregoing, “Good Reason”
shall not be deemed to have occurred unless: (A) you provide the Company with written notice that you intend to terminate
your employment hereunder for one of the grounds set forth in subsections (i), (ii), (iii) or (iv) within sixty (60) days
of such reason(s) occurring, (B) if such ground is capable of being cured, the Company has failed to cure such ground within
a period of thirty (30) days from the date of such written notice, and (C) you terminate your employment within six (6) months
from the date that Good Reason first occurs. For purposes of clarification, the above-listed conditions shall apply separately
to each occurrence of Good Reason and failure to adhere to such conditions in the event of Good Reason shall not disqualify you
from asserting Good Reason for any subsequent occurrence of Good Reason.

 

		(e)	Release of Claims. The Company shall not be obligated to pay you the severance payments
provided for herein unless you have timely executed (and not revoked) a separation agreement in substantially the form attached
hereto as Exhibit A. Such separation agreement must be executed and become binding and enforceable within sixty (60) calendar
days after the effective date of your termination of employment (such 60th day, the “Payment Commencement Date,”).
Subject to the preceding sentence, payment of any severance payments due hereunder shall commence on the Payment Commencement Date.

 

		4.	Parachute Payment. 

	 	 	 
		(a)	In the event of a consummation of a change in ownership or control (within the meaning of Section
280G of the Code and the regulations thereunder (“Section 280G”) (a “280G Change in Control”)
(as defined herein) payments and benefits under this Agreement, together with other payments and benefits provided to you by the
Company (including, without limitation, any accelerated vesting of stock options, shares of restricted stock or other equity-based
awards) (the “Total Payments”), shall be made with regard to whether the deductibility of the Total Payments
would be limited or precluded by Section 280G and without regard to whether the Total Payments would subject you to the federal
excise tax levied on certain “excess parachute payments” under Section 4999 of the Code (the “Excise Tax”).
If any portion of the Total Payments constitutes an “excess parachute payment” within the meaning of Section 280G (the
aggregate of such payments (or portions thereof) being hereinafter referred to as the “Excess Parachute Payments”),
You will be entitled to receive: (i) an amount limited so that no portion thereof shall fail to be tax deductible under Section
280G of the Code (the “Limited Amount”), or (ii) if the amount otherwise payable hereunder or otherwise (without regarding
to clause (i)) reduced by all taxes applicable thereto (including, for the avoidance of doubt, the Excise Tax) would be greater
than the Limited Amount reduced by all taxes applicable thereto, the amount otherwise payable hereunder.
	 	 	 
	

    	A-4

     

    

	 	 	 

		(b)	The determination as to whether the Total Payments include Excess Parachute Payments and, if so,
the amount of such Excess Parachute Payments, the amount of any Excise Tax with respect thereto, the amount of any Gross-up Payment,
if applicable, and the amount of any reduction in Total Payments shall be made at the Company’s expense by the independent
public accounting firm most recently serving as the Company’s outside auditors or such other accounting or benefits consulting
group or firm as the Company may designate (the “Accountants”). In the event that any payments under this Agreement
or otherwise are required to be reduced as described in Section 4(b), the adjustment will be made, first, by reducing the amount
of base salary and bonus payable pursuant to Sections 3(a)(i) or the amount of base salary and bonus payable pursuant to
Section 3(b)(i)-(ii), as applicable; second, if additional reductions are necessary, by reducing the payment of or reimbursement
for COBRA premiums due to you pursuant to Section 3(a)(ii) or Section 3(b)(iii), as applicable; and third,
if additional reductions are still necessary, by eliminating the accelerated vesting of time-based equity-based awards or the vesting
of performance-based equity-based awards, if any, starting with those awards for which the amount required to be taken into account
under Section 280G is the greatest.
	 	 	 

		(c)	In the event that there has been an underpayment or overpayment under this Agreement or otherwise
as determined by the Accountants, the amount of such underpayment or overpayment shall forthwith be paid to you or refunded to
the Company, as the case may be, with interest at the applicable federal rate provided for in Section 7872(f) (2) of the Code.

 

		5.	Prohibited Competition and Solicitation. You acknowledge the competitive and proprietary
aspects of the business of Company and are aware that the Company furnishes, discloses and makes available to you confidential
and Proprietary Information (as defined in the Confidentiality Agreement referenced in Section 8 below) related to Company’s
business and that Company may provide you with unique and specialized knowledge and training. You also acknowledge that the Confidential
Information and specialized knowledge and training have been developed and will be developed by Company through the expenditure
of substantial time, effort and money and that the Confidential Information could be used by you to compete with Company. A business
will be deemed to be “Competitive” with the Company if it performs research, development or commercialization of individualized
cell-based therapy for the treatment of metastatic renal cell carcinoma, HIV or another indication in which the Company has conducted
a clinical trial within twelve months before the end of your employment with the Company. Because of the competitive and proprietary
aspects of the business of the Company, you agree as follows:

 

(a) Covenant Not to Compete
or Solicit. During your employment with the Company and for one (1) year after the termination of your employment
with Company for any reason, you will not, directly or indirectly, on your behalf or on behalf of another person, entity or third
party anywhere in the United States, engage in the following conduct without the prior written consent of Company: (i) as officer,
director, principal, agent, stockholder, employee, consultant, representative or in any other capacity, own, manage, operate or
control, or be employed by, provide services to, or engage in or have a financial interest in any business which is Competitive
with Company (other than as specifically permitted by the Company in writing upon written request); (ii) solicit, divert or appropriate
or attempt to solicit, divert or appropriate, the business or patronage of any customers, business partners, or patrons of Company,
or any prospective customers, business partners, or patrons to whom the Company has made a sales presentation (or similar offering
of services or business) within the one (1) year period preceding the date of your termination of employment with Company; (iii)
solicit, entice or persuade or attempt to solicit, entice or persuade any employees of or consultants to Company or any present
or future parent, subsidiary or affiliate of Company to terminate their employment or other engagement with Company or any such
parent, subsidiary or affiliate for any reason; or (iv) interfere with, or attempt to interfere with, the relations between Company
and any customer, vendor or supplier to Company.

 

(b) Reasonableness of Restrictions.
You acknowledges that: (i) the types of employment which are prohibited by this Section 5 are narrow and reasonable in relation
to the skills which represent your principal salable asset both to Company and other prospective employers; and (ii) the temporal
and geographical scope of Section 5 is reasonable, legitimate and fair to you in light of Company’s need to market its services
and sell its products in order to have a sufficient customer base to make Company’s business profitable and in light of the
limited restrictions on the type of employment prohibited herein compared to the types of employment for which you are qualified
to earn your livelihood.

 

		6.	Section 409A.

 

		(a)	You and the Company agree that this Agreement shall be interpreted to comply with or be exempt
from Section 409A, and the regulations and guidance promulgated thereunder to the extent applicable, and all provisions of
this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Section 409A.

 

    	A-5

     

    

 

		(b)	A termination of employment shall not be deemed to have occurred for purposes of any provision
of this Agreement providing for the payment of any amounts or benefits considered “nonqualified deferred compensation”
under Section 409A upon or following a termination of employment unless such termination is also a “separation from
service” within the meaning of Section 409A and, for purposes of any such provision of this Agreement, references to
a “termination,” “termination of employment” or like terms shall mean “separation from service.” 
If you are deemed on the date of termination to be a “specified employee” within the meaning of that term under Section 409A(a)(2)(B),
then with regard to any payment or the provision of any benefit that is considered nonqualified deferred compensation under Section 409A
payable on account of a “separation from service,” such payment or benefit shall be made or provided at the date which
is the earlier of (a) the expiration of the six-month period measured from the date of such “separation from service,”
and (b) the date of your death (the “Delay Period”).  Upon the expiration of the Delay Period, all payments
and benefits delayed pursuant to this Section 11(b) (whether they would have otherwise been payable in a single sum or
in installments in the absence of such delay) shall be paid or reimbursed on the first business day following the expiration of
the Delay Period to you in a lump sum, and any remaining payments and benefits due under this Agreement shall be paid or provided
in accordance with the normal payment dates specified for them herein.

 

		(c)	For purposes of Section 409A, your right to receive any installment payments pursuant to this
Agreement shall be treated as a right to receive a series of separate and distinct payments.

 

		(d)	In no event shall the Company or any of its affiliates have any liability relating to the failure
or alleged failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A

 

		7.	At Will Employment. This Offer Letter is not intended to, nor does it, create any employment
contract for any specified term or duration between you and the Company. In accordance with the laws of the State of North Carolina,
your employment with the Company is considered “at will”. This means that, just as you may resign your employment at
any time, Argos Therapeutics may, in its sole discretion, with or without cause, terminate your employment at any time for any
reason.

 

		8.	Contingencies. This offer of employment includes a 90 day introductory period which is outlined
in the Company’s Employee Handbook, and is also contingent upon the following: satisfactory completion of the Argos Therapeutics
employment application; your ability to begin work on the date indicated below; proof of your authorization to work in the United
States (I-9 Employment Eligibility Verification); execution of a Confidentiality, Inventions and Non-Solicitation Agreement (the
“Confidentiality Agreement”); execution of the Argos Therapeutics Company’s Code of Ethics; execution
of the Argos Therapeutics Certification Regarding Insider Trading and Public Disclosure Policies; and passing a pre-employment
drug screening and background screening to Management’s satisfaction. It is understood and agreed that breach by you of the
Confidentiality Agreement shall constitute a material breach of this Agreement

 

		9.	No Conflicting Agreements. You represent and warrant that you are not bound by any employment
contract, restrictive covenant or other restriction preventing you from continuing employment with or carrying out your responsibilities
for the Company. You agree that you will not disclose or use on behalf of the Company any proprietary information of any third
party without that party’s consent.

 

		10.	General.

 

		(a)	Notices.  Any notices provided for in this Agreement shall be in writing and shall
be effective when delivered in person, consigned to a reputable national courier service for overnight delivery or deposited in
the United States mail, postage prepaid, and addressed to you at your last known address on the books of the Company or, in the
case of the Company, to it by notice to the Chairman of the Board of Directors, c/o Argos Therapeutics, Inc., at its principal
place of business, or to such other address(es) as either party may specify by notice to the other actually received.

 

    	A-6

     

    

 

		(b)	Entire Agreement. This Offer Letter, together with the Confidentiality Agreement and other
agreements specifically referred to herein, sets forth the entire agreement between you and the Company and replaces all prior
communications, agreements and understandings, whether oral or written, with respect to your and understandings relating to your
employment with the Company. The terms and conditions of this Agreement may only be modified or amended by a written agreement
executed by and the Company.

		(c)	Successors and Assigns. The Company may assign its rights and obligations hereunder to any
person or entity that succeeds to all or substantially all of Company’s business or that aspect of Company’s business
in which you are principally involved. You may not assign your rights and obligations under this Agreement without the prior written
consent of Company.

 

		(d)	Severability.  If any portion or provision of this letter Agreement is deemed to any
extent illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement will not be affected
and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law

 

		(e)	Governing Law and Venue. This letter shall be governed
by and construed in accordance with the laws of the State of North Carolina (without reference to the conflicts of law provisions
thereof). Any action, suit, or other legal proceeding which is commenced to resolve any matter arising under or relating to any
provision of this letter shall be commenced only in a court in Durham County, North Carolina (or, if appropriate, a federal court
located within North Carolina). 

		(f)	Counterparts. This Agreement may be executed in two or more counterparts, each of which
will be deemed an original and all of which together shall constitute one and the same instrument. A signature by fax shall be
treated as an original.

 

By your signature below, you represent and warrant to the Company
that you: (i) are not subject to any employment, noncompetition or other similar agreement that would prevent or interfere with
the Company’s employment of you on the terms set forth herein; and (ii) have not brought and will not bring with you to the
Company, any materials or documents of a former employer which are not generally available to the public or which did not belong
to you prior to your employment with the Company, unless you have obtained written authorization from the former employer or other
owner for their possession and use and provided the Company with a copy thereof.

 

If our employment offer is satisfactory, please sign and date a
copy of this letter in the space provided below as well as the accompanying documents, including the Confidentiality Agreement,
Code of Ethics, and Certification Regarding Insider Trading and Public Disclosure Policies and return them Joan Winterbottom, VP
and Chief Human Resources Officer, no later than Thursday, December 3, 2015. If the offer is not accepted by this date, it shall
expire. At the time you sign and return it, this Offer Letter will take effect as a binding agreement between you and the Company
on the basis set forth above.  We are looking forward to working with you in contributing to the growth of Argos Therapeutics.

 

 

Sincerely,

 

 

 

Jeffrey D. Abbey

President & CEO

 

Enclosures (as stated)

 

I accept the Company’s employment offer for the position of
Chief Medical Officer subject to the terms and conditions outlined above.

 

	Signed:  	 	 	 
	 	 	 	 
	Printed Name:   	 	 	 
	 	 	 	 
	Date Signed:  	 	Start Date:   	 

 

 

    	A-7

     

    

EXHIBIT A

 

SEPARATION AGREEMENT AND RELEASE OF CLAIMS 

 

Argos Therapeutics, Inc., a Delaware corporation
(the “Company”), and Lee F. Allen (the “Employee”) (together, the “Parties”)
accepted an offer of employment with the Company pursuant to the terms of the offer letter dated December 2, 2015 (the “Offer
Letter”). Any capitalized terms not defined herein shall have the meanings ascribed to them in the Offer Letter. This
is the release by Employee of all claims against the Releasees (as defined below) arising out of the Employee’s employment
with or separation from the Company (the “Release”). The consideration for the Employee’s agreement to
this Release consists of the severance payments and benefits set forth in Section 3 of the Offer Letter, which are conditioned
on, among other things, termination of the Employee’s employment by the Company without Cause or by the Employee for Good
Reason and effectiveness of this Release based on the Employee’s timely execution and non-revocation hereof.

 

1. Tender of Release. This Release
is automatically tendered to the Employee upon the termination of the Employee’s employment by the Company without Cause
or by the Employee with Good Reason.

 

2. Release of Claims. The Employee
voluntarily, fully, forever, irrevocably and unconditionally releases and discharges the Company, its affiliates, subsidiaries
and parent companies and each of their predecessors, successors, assigns, and their current and former members, partners, directors,
managers, officers, employees, representatives, attorneys, agents, and all persons acting by, through, under or in concert with
any of the foregoing (any and all of whom or which are hereinafter referred to as the “Releasees”), from any
and all charges, complaints, claims, liabilities, obligations, promises, agreements, controversies, damages, actions, causes of
action, suits, rights, demands, costs, losses, debts and expenses (including attorney’s fees and costs actually incurred),
of any nature whatsoever, known or unknown that the Employee now has, owns or holds, or claims to have, own, or hold, or that he
at any time had, owned, or held, or claimed to have had, owned, or held against any Releasee arising out of the Employee’s
employment with or separation from the Company (collectively, “Claims”). This release of Claims includes, without
implication of limitation, the release of all Claims:

 

	 	•	 	of breach of contract; 

 

	 	•	 	of retaliation or discrimination under federal, state or local law (including, without limitation, Claims of age discrimination or retaliation under the Age Discrimination in Employment Act, Claims of disability discrimination or retaliation under the Americans with Disabilities Act, Claims of discrimination or retaliation under Title VII of the Civil Rights Act of 1964 and Claims of discrimination or retaliation under state law); 

 

	 	•	 	under any other federal or state statute, to the fullest extent that Claims may be released; 

 

	 	•	 	of defamation or other torts; 

 

	 	•	 	of violation of public policy; 

 

	 	•	 	for wages, salary, bonuses, vacation pay or any other compensation or benefits; and 

 

	 	•	 	for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages, injunctive relief and attorney’s fees. 

 

Notwithstanding anything to the contrary contained herein, this
Release does not apply to or affect (i) the Employee’s right to receive the severance payments set forth in Section 3
of Offer Letter , (ii) the Employee’s right to be reimbursed for reasonable business expenses incurred prior to termination
of the Employee’s employment according to the terms of Section 2(e) of the Offer Letter; (iii) the Employee’s ownership
of, and the Employee’s rights by virtue of his ownership of, any capital stock or other securities of the Company, (iv) any
rights of indemnification or exculpation of which the Employee is the beneficiary under any separate contractual indemnification
agreement with the Company in connection with his service as a director or officer of the Company, the corporate charter, bylaws
or other charter or organizational instruments or benefit or equity plans of the Company or any other Releasee or at law and rights
of coverage to which the Employee may be entitled under any director and officer liability insurance policy of the Company or any
other Releasee or (v) for purposes of clarity, any Claim arising out of any matters or events occurring after the effective
date of the Release.

 

    	A-8

     

    

4. Ongoing Obligations of the Employee;
Enforcement Rights. The Employee reaffirms his ongoing obligations as well as the Company’s enforcement rights provided
for in Sections 6, 7 and 8 of the Offer Letter.

 

5. No Assignment; Representation on Action.
The Employee represents that he has not assigned to any other person or entity any Claims against any Releasee. The Employee further
represents that he has not filed or reported any Claims against any Releasee with any state, federal or local agency or court.

 

6. Right to Consider and Revoke Release.
The Employee acknowledges that he has been given the opportunity to consider this Release for a period ending forty-five (45) days
after the tender of the Release. In the event the Employee executed this Release within less than forty-five (45) days after the
tender of the Release, he acknowledges that such decision was entirely voluntary and that he had the opportunity to consider this
Release until the end of the forty-five (45) day period. To accept this Release, the Employee shall deliver a signed Release
to the Chairman of the Compensation Committee of the Board (the “Chair”) within such forty-five (45) period.
For a period of seven (7) days from the date when the Employee executes this Release (the “Revocation Period”),
he shall retain the right to revoke this Release by written notice that is received by the Chair on or before the last day of the
Revocation Period. This Release shall take effect only if it is executed within the forty-five (45) day period as set forth
above and if it is not revoked pursuant to the preceding sentence. If those conditions are satisfied, this Release shall become
effective and enforceable on the date immediately following the last day of the Revocation Period.

 

7. Other Terms.

 

(a) Legal Representation; Review of Release.
The Employee acknowledges that he has been advised to discuss all aspects of this Release with his attorney, that he has carefully
read and fully understands all of the provisions of this Release and that he is voluntarily entering into this Release.

 

(b) Binding Nature of Release. This
Release shall be binding upon the Employee and upon his heirs, administrators, representatives and executors.

 

(c) Modification of Release; Waiver.
This Release may be amended, only upon a written agreement executed by the Employee and the Company.

 

(d) Severability. In the event that
at any future time it is determined by an arbitrator or court of competent jurisdiction that any covenant, clause, provision or
term of this Release is illegal, invalid or unenforceable, the remaining provisions and terms of this Release shall not be affected
thereby and the illegal, invalid or unenforceable term or provision shall be severed from the remainder of this Release. In the
event of such severance, the remaining covenants shall be binding and enforceable.

 

(e) Governing Law and Venue. This Release
shall be deemed to be made and entered into in the State of North Carolina and shall in all respects be interpreted, enforced and
governed under the laws of the State of North Carolina without giving effect to the conflict of law provisions of North Carolina
law that would require the application of law of any other jurisdiction. The language of all parts of this Release shall in all
cases be construed as a whole, according to its fair meaning, and not strictly for or against either of the Parties.
Any action, suit or other legal proceeding which is commenced to resolve any matter arising under or relating to any provision
hereunder shall be commenced only in a court in Durham County, North Carolina (or, if appropriate, a federal court located within
North Carolina). 

 

(f) Absence of Reliance. The Employee
acknowledges that he is not relying on any promises or representations by the Company or its agents, representatives or attorneys
of either of them regarding any subject matter addressed in this Release.

 

 

    	A-9

     

    

So agreed by the Employee:

 

	 	 	 
	Lee F. Allen	 	Date
	 	 	 
	 	 	 
	 	 	 

 

 

 

 

 

 

 

 

A-10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00258-of-00352.parquet"}]]